News archive
Showing 680 results
March 2015
-
Media Release
Novartis presents Cosentyx™ two-year efficacy and safety data showing sustainable effect in psoriasis patients
- New data at AAD shows 7 out of 10 psoriasis patients who were PASI 75 responders at 52 weeks achieved clear to almost clear skin (PASI 90) after two years of Cosentyx 300 mg treatment- After two… -
Media Release
Novartis presents Cosentyx™ two-year efficacy and safety data showing sustainable effect in psoriasis patients
-
Media Release
New Novartis data show more Cosentyx™-treated psoriasis patients achieved clear or almost clear skin (PASI 90) compared to Stelara®
- Phase IIIb CLEAR study at AAD showed over 21% more psoriasis patients achieved clear to almost clear skin (PASI 90) with Cosentyx™ (secukinumab) compared to Stelara® (ustekinumab) at Week 16- In… -
Media Release
New Novartis data show more Cosentyx™-treated psoriasis patients achieved clear or almost clear skin (PASI 90) compared to Stelara®
February 2015
-
Media Release
Novartis' heart failure medicine LCZ696 granted FDA priority review
- Decision could speed access to LCZ696 for heart failure with reduced ejection fraction patients in the US, reducing total review time from 12 to 8 months(1) - Filing is based on results from the… -
Media Release
Novartis' heart failure medicine LCZ696 granted FDA priority review
January 2015
-
Media Release
Novartis announces FDA approval for first IL-17A antagonist Cosentyx™ (secukinumab) for moderate-to-severe plaque psoriasis patients
- Phase III data demonstrated Cosentyx resulted in clear or almost clear skin in the majority of patients with moderate-to-severe plaque psoriasis- Offering a new treatment option for patients,… -
Media Release
Novartis announces FDA approval for first IL-17A antagonist Cosentyx™ (secukinumab) for moderate-to-severe plaque psoriasis patients
December 2014
-
Media Release
Novartis gains FDA approval for Signifor® LAR to treat patients with acromegaly, a rare and life-threatening hormonal disorder
Acromegaly is an endocrine disorder caused by elevated growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels(1)Signifor LAR, a next-generation somatostatin analog, provides a new option… -
Media Release
Novartis gains FDA approval for Signifor® LAR to treat patients with acromegaly, a rare and life-threatening hormonal disorder
-
Media Release
Novartis gains FDA approval for Signifor® LAR to treat patients with acromegaly, a rare and life-threatening hormonal disorder
-
Media Release
Novartis highlights new CTL019 clinical data showing complete remissions in children and young adults with relapsed/refractory acute lymphoblastic leukemia
- Data shows 36 of 39 pediatric patients with relapsed/refractory acute lymphoblastic leukemia (r/r ALL) (92%) experienced complete remissions[1]- Additionally, sustained remissions were achieved up…